Medivir’s nucleotide polymerase inhibitor for the

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 1, 2016 at 11:15 AM

Medivir’s nucleotide polymerase inhibitor for the treatment of liver cancer, MIV-818, enters non-clinical development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV -818 has been selected as a candidate drug (CD) from its nucleotide DNA polymerase inhibitor project for the treatment of hepatocellular carcinoma (HCC), and has now entered non-clinical development. Liver cancers are orphan indications in North American and Western European markets. However they are the second leading cause of cancer-related death worldwide, and one of the fastest growing forms of cancer in the US, based on incidence and mortality. Hepatocellular carcinoma (HCC) is the most common cancer of the liver. Despite improvements in the detection and management of the disease, the 5-year survival rate for patients in the USA who are diagnosed with liver cancer remains below 20%. While curative surgical treatments are available to HCC patients who are diagnosed early in their disease, the prognosis for all inoperable HCC cases remains poor. There is consequently an urgent need for improved treatments, particularly for patients with advanced stages of HCC and other forms of liver cancer. Effective therapies for patients with inoperable intermediate HCC include the delivery of drugs directly to the cancer tumour through the liver’s blood supply, which is technically challenging and for which many patients are ineligible. In contrast, most anticancer drugs that are widely distributed throughout the body are ineffective. Sorafenib is the only orally administered drug used to treat liver cancer. It is approved for use in patients with advanced HCC but confers only modest survival benefits. Despite these limitations, sorafenib has achieved over $1B in annual worldwide sales across several cancer indications, with the majority of sales from treatment of HCC. Medivir has developed substantial capabilities to selectively deliver the active metabolites of nucleoside and nucleotide analogues to the liver, based on its long-standing interests in discovering improved treatments for chronic hepatitis B virus and hepatitis C virus infections. MIV-818 is a potent and selective inhibitor of the proliferation of liver cancer cell lines that has been designed to deliver high levels of the active drug selectively to the liver. MIV-818 has the potential to become the first liver-targeted orally administered drug to address HCC and other liver cancers. Medivir expects to communicate the preclinical antitumour and pharmacokinetic profile of MIV-818 at major scientific meetings in 2017. “MIV-818 is unique in that it is an orally administered chemotherapeutic that will be developed exclusively for liver cancers. Many treatments that were successful in other cancers have failed to provide benefits to liver cancer patients, often because systemic toxicity prevents effective drug concentrations from being reached at the tumour site. We have designed MIV-818 to be liver -directed in order to overcome these limitations, and we look forward to advancing it into clinical trials as rapidly as possible.” said Richard Bethell, Chief Scientific Officer, Medivir AB. “We are delighted to have delivered the first CD from our internal portfolio of early-stage anti-cancer and immuno -oncology projects since it represents an important milestone in our transition to being an exclusively oncology-focused pharmaceutical company.” For further information, please contact: Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580 Richard Bethell, CSO Medivir AB, mobile +46 (0)72 704 3211 This information is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the CFO set out above, at 15.45 CET on 1 November, 2016. About Medivir Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Classic vs. Youngtimer Cars: Evolution in Collecting

The Collector's Journey: Classic Cars vs. Youngtimers Ever notice how car collecting has its own circles of fame? You're either basking in the glow of a vintage classic or eyeing a youngtimer that’s just catching steam. In this article from HelloNation, Engels Gualdani — the classic car sage of Hilton, NY — helps untangle these categories for us, and it’s a lesson...

Smart Banner Choices: Decisions Beyond Design

By Caleb Price Updated Nov 13, 2026 Category News Views 152

Location, Location, Location: Banner Insights Picking a banner isn't just a quick snap decision. You got to think big, and location is a starting line. Adam Norsworthy from Minuteman Press underscores that understanding how and where this piece of publicity will hang matters more than you might guess. Outdoor or indoor isn't just a weather question; it's a matter of...

PangeAI and Sky Blue Transform Data Center Decisions

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...

Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Toys"R"Us Rolls Out 160 U.S. Stores, NYC Celebration

Rebuilding the Toy Empire After a rough few years, Toys"R"Us is clawing its way back into the hearts—and wallets—of American shoppers. With 160+ new standalone stores popping up like mushrooms after rain, these guys aren't just playing games. This is a strategic move to reestablish their presence in the retail landscape just before the holiday shopping frenzy kicks...

Nagarro's Earnings Show Stagnant Growth Amid Flat Margins

Nagarro's Financial Picture: A Glimpse Live a day in the trading pits and you'll learn to spot when a company is merely treading water. That's the vibe I'm getting from Nagarro's Q3 2026 results. They might label themselves as an AI-native leviathan, but these numbers spell out a story of struggle wrapped in fancy buzzwords. Revenue Uptick or Revenue Hiccup? For the nine...

APEC Summit 2026: Shenzhen in the Spotlight

An International Stage for Shenzhen Alright, folks, here's the deal. We’ve got the 2026 APEC Summit rolling into Shenzhen, perched right there in Guangdong Province, and the world’s eyes are glued to it. Happens November 18–19, and you better believe it’s a magnet for all things global. The China Media Group’s Chinese Global Program Center isn’t missing a...

Endava Faces Class Action: Investor Reactions and Next Steps

Trouble at Endava: Leadership Shakeup and Financial Concerns So, here's the kicker—Endava's got itself into one mighty mess worth chewing over with your morning coffee. When your top brass drops like flies, and you're fumbling your financials, investors start sweating bullets. On October 28, 2026, Endava plc (NYSE: DAVA) confesses to some serious accounting missteps....

First Horizon's $25M Bet: New Center Transforms Houston

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

Perpetua Reports Q3 2026 Results, Progress on Project

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...